Abstract:IMPORTANCE: The dream enactment of rapid eye movement sleep behavior disorder (RBD) is often the first indication of an impending α-synuclein disorder, such as Parkinson disease, multiple-system atrophy, or dementia with Lewy bodies.OBJECTIVE: To provide an overview of RBD from the onset of dream enactment through the emergence of a parkinsonian disorder.EVIDENCE REVIEW: Peer-reviewed articles, including case reports, case series, retrospective reviews, prospective randomized trials, and basic science investigations, were identified in a PubMed search of articles on RBD from January 1, 1986, through July 31, 2014.FINDINGS: Under normal conditions, vivid dream mentation combined with skeletal muscle paralysis characterizes rapid eye movement sleep. In RBD, α-synuclein abnormalities in the brainstem disinhibit rapid eye movement sleep motor activity, leading to dream enactment. The behaviors of RBD are often theatrical, with complexity, aggression, and violence; fighting and fleeing actions can be injurious to patients as well as bed partners. Rapid eye movement sleep behavior disorder is distinguished from other parasomnias by clinical features and the demonstration of rapid eye movement sleep without atonia on polysomnography. Consistent with early neurodegeneration, patients with RBD demonstrate subtle motor, cognitive, and autonomic impairments. Approximately 50% of patients with spontaneous RBD will convert to a parkinsonian disorder within a decade. Ultimately, nearly all (81%-90%) patients with RBD develop a neurodegenerative disorder. Among patients with Parkinson disease, RBD predicts a non-tremor-predominant subtype, gait freezing, and an aggressive clinical course. The most commonly cited RBD treatments include low-dose clonazepam or high-dose melatonin taken orally at bedtime.CONCLUSIONS AND RELEVANCE: Treatment of RBD can prevent injury to patients and bed partners. Because RBD is a prodromal syndrome of Parkinson disease (or related disorder), it represents a unique opportunity for developing and testing disease-modifying therapies.

“Idiopathic” Rapid-Eye-Movement (REM) Sleep Behavior Disorder Is Associated With Future Development of Neurodegenerative Diseases

Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study

Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases

Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Disease

Morbidities in rapid eye movement sleep behavior disorder

Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update

Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study

History of symptoms consistent with REM sleep behavior disorder in a population with Parkinson's Disease

RBD and Neurodegenerative Diseases.

Mortality and Its Risk Factors in Patients with Rapid Eye Movement Sleep Behavior Disorder

Considering REM Sleep Behavior Disorder in the Management of Parkinson’s Disease

Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies

Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions

Electroencephalographic Finding in Idiopathic REM Sleep Behavior Disorder

Excessive Daytime Sleepiness Predicts Neurodegeneration in Idiopathic REM Sleep Behavior Disorder

Early- and late-onset of isolated rapid eye movement sleep behavior disorder: A retrospective cohort study

Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder

Insomnia and somnolence in idiopathic RBD: a prospective cohort study

Sleep Disturbances and Phenoconversion in Patients with REM Sleep Behavior Disorder

Rapid eye movement sleep behaviour disorder in children and adolescents

Wider and Faster Degeneration of White Matter in Parkinson’s Disease with Possible REM Sleep Behaviour Disorder